CHEK2 and ovarian carcinoma: This finding is consistent with a recent report that high expression of Chk2 is associated with better response towards platinum-based chemotherapy in EOC patients, and knockdown of Chk2 renders ovarian cancer more resistant against platinum-based chemotherapy [39].